Company Overview and News

 
What's in the Cards for Genuine Parts (GPC) in Q1 Earnings?

2018-04-16 zacks
Genuine Parts Company (GPC - Free Report) is set to report first-quarter 2018 results before the opening bell on Apr 19.
Upvote Downvote

 
OSK / Oshkosh Corporation (Holding Company) null (Current Report)

2018-04-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
Is Oshkosh (OSK) a Great Stock for Value Investors?

2018-04-02 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
Upvote Downvote

 
Zacks Value Investor Highlights: BP, Cigna, Meritage Homes, Oshkosh and Realogy Holdings

2018-03-15 zacks
Chicago, IL – March 15, 2018 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/295673/how-to-screen-for-classic-value-stocks)
Upvote Downvote

 
How to Screen for Classic Value Stocks

2018-03-14 zacks
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service, shares some of her top value investing tips and stock picks.
Upvote Downvote

4
Stocks To Watch: Back To Basics Time

2018-03-10 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Upvote Downvote

 
Vehicle Assembly Unit Drives Magna, North America Sales Dip

2018-03-06 zacks
On Mar 5, we issued an updated research report on Magna International Inc. (MGA - Free Report) .
Upvote Downvote

 
Ford Seeks Clarity on Brexit to Frame UK Investment Plans

2018-03-06 zacks
Ford Motor Company (F - Free Report) stated that it needs clarification on the trading conditions in the aftermath of Brexit, per Reuters. Ample clarification on all aspects of trade is required to make any concrete investment decision in Britain. Significantly, Britain is Europe's second-largest automotive market. Following a referendum in 2016, the country is scheduled to leave European Union (EU) by the end of March 2019.
Upvote Downvote

4
Why Carl Icahn Just Cut His Manitowoc Stake By 33%

2018-02-23 seekingalpha
A schedule 13D filed with the SEC this afternoon revealed that Icahn Capital Management reduced its stake in Manitowoc Company Inc by $31.3 million.
Upvote Downvote

1
Carl Icahn Just Cut His Manitowoc Company Inc (MTW) Stake By 33% - ValueWalk

2018-02-23 valuewalk
On February 14th, Carl Icahn’s firm Icahn Capital Management filed its quarterly Form 13F regulatory filing. The filing showed that the investment firm held 2,645,657 shares of Manitowoc worth $104.1 million as of December 31st.
Upvote Downvote

 
OSK / Oshkosh Corporation (Holding Company) / Aristotle Capital Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (AMENDMENT NO. 2)*   OSHKOSH Corporation (Name of Issuer)   Common Stock, Par Value of $.01 Per Share   688239201 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of This Statement)   Check the appropriate box to designate the rule pursuan
Upvote Downvote

 
OSK / Oshkosh Corporation (Holding Company) / Aristotle Capital Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (AMENDMENT NO. 1)*   OSHKOSH Corporation (Name of Issuer)   Common Stock, Par Value of $.01 Per Share   688239201 (CUSIP Number)   December 31, 2016 (Date of Event Which Requires Filing of This Statement)   Check the appropriate box to designate the rule pursuan
Upvote Downvote

 
OSK / Oshkosh Corporation (Holding Company) / Aristotle Capital Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (AMENDMENT NO. 2)*   OSHKOSH Corporation (Name of Issuer)   Common Stock, Par Value of $.01 Per Share   688239201 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of This Statement)   Check the appropriate box to designate the rule pursuan
Upvote Downvote

 
OSK / Oshkosh Corporation (Holding Company) / Aristotle Capital Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (AMENDMENT NO. 1)*   OSHKOSH Corporation (Name of Issuer)   Common Stock, Par Value of $.01 Per Share   688239201 (CUSIP Number)   December 31, 2016 (Date of Event Which Requires Filing of This Statement)   Check the appropriate box to designate the rule pursuan
Upvote Downvote

 
OSK / Oshkosh Corporation (Holding Company) / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Oshkosh Corp (Name of Issuer) Common Stock (Title of Class of Securities) 688239201 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 688239201